Image

Data Gathering for A10900

Data Gathering for A10900

Recruiting
22 years and older
All
Phase N/A

Powered by AI

Overview

The objective of this study is to gather Optical Coherence Tomography (OCT) data on normal and diseased eyes

Eligibility

Inclusion/Exclusion Criteria Inclusion Criteria for Retinal Disease Group

  1. Participants 22 years of age or older on the date of informed consent
  2. Participants able to understand the written informed consent and willing to participate as evidenced by signing the informed consent
  3. BCVA 20/400 or better in the study eye
  4. Participants presenting at the site with retinal disease
  5. Diagnosis of some type of retinal pathology by investigator, may include, but not limited to: Macular Degeneration (including participants with drusen and geographic atrophy and choroidal neovascularization), Diabetic Macular Edema, Diabetic Retinopathy, Macular Hole, Epiretinal Membrane, Central Serous Retinopathy and others

Exclusion Criteria for Retinal Disease Group

  1. Participants unable to tolerate ophthalmic imaging
  2. Participants not able to obtain acceptable OCT images due to ocular media opacity or other reasons
  3. Participant has a condition or is in a situation which the investigator feels may put the participant at significant risk, may confound the study results, or may interfere significantly with the participant's participation in the study
  4. Presence of glaucoma or any ocular pathology other than a retinal pathology in the study eye as determined by self-report and/or investigator assessment at the study visit;

Inclusion Criteria for Glaucoma Group

  1. Participants 22 years of age or older on the date of informed consent
  2. Participants able to understand the written informed consent and willing to participate as evidenced by signing the informed consent
  3. BCVA 20/40 or better in the study eye
  4. History of Visual field defects within the previous year from the study visit or measured the day of the study visit consistent with glaucomatous optic nerve damage with at least one of the following two findings:
    1. On pattern deviation (PD), there exists a cluster of 3 or more points in an expected location of the visual field depressed below the 5% level, at least 1 of which is depressed below the 1% level;
    2. Glaucoma hemi-field test "outside normal limits."
  5. Glaucomatous optic nerve damage as evidenced by any of the following optic disc or

    retinal nerve fiber layer structural abnormalities:

    1. Diffuse thinning, focal narrowing, or notching of the neuroretinal rim, especially at the inferior or superior poles with or without disc hemorrhage;
    2. Optic disc neural rim asymmetry of the two eyes consistent with loss of neural tissue

Exclusion Criteria for Glaucoma Group

  1. Participants unable to tolerate ophthalmic imaging
  2. Participants not able to obtain acceptable OCT images due to ocular media opacity or other reasons
  3. Participant has a condition or is in a situation which the investigator feels may put the participant at significant risk, may confound the study results, or may interfere significantly with the participant's participation in the study
  4. No reliable visual field test result within the previous year from the study visit, defined as fixation losses > 33% or false positives > 33%, or false negatives > 33% in the study eye
  5. Presence of any ocular pathology except glaucoma in the study eye Inclusion Criteria for Corneal Group
    1. Participants 22 years of age or older on the date of informed consent 2. Participants able to understand the written informed consent and willing to participate as evidenced by signing the informed consent 3. Participants presenting at the site with corneal disease, for example but not limited to, corneal disorders due to contact lens wear, post-refractive surgery, dry eye, keratoconus 4. Participant is able to comply with the study procedures.

Exclusion Criteria for Corneal Group

  1. Participants unable to tolerate ophthalmic imaging
  2. Participant has a condition or is in a situation which the investigator feels may put the participant at significant risk, may confound the study results, or may interfere significantly with the participant's participation in the study
  3. Participant with ocular media not sufficiently clear to obtain acceptable OCT images.

Inclusion Criteria for Normal Group

  1. Participants 22 years of age or older on the date of informed consent
  2. Participants able to understand the written informed consent and willing to participate as evidenced by signing the informed consent
  3. Participants presenting at the site with normal eyes (Cataracts, LASIK, PRK, and peripheral pathology that does not affect the posterior pole region, for example lattice and peripheral drusen, are allowed).
  4. BCVA 20/40 or better (each eye)
  5. Participant is able to comply with the study procedures

Exclusion Criteria for Normal Group

  1. Participants unable to tolerate ophthalmic imaging
  2. Participant has a condition or is in a situation which the investigator feels may put the participant at significant risk, may confound the study results, or may interfere significantly with the participant's participation in the study
  3. Participant with ocular media not sufficiently clear to obtain acceptable OCT images
  4. History of leukemia, dementia or multiple sclerosis

Study details
    Retinal Disease
    Healthy
    Glaucoma
    Corneal Diseases

NCT07149740

Optos, PLC

15 October 2025

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.